Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Note 18 - Segmented Information

v3.10.0.1
Note 18 - Segmented Information
12 Months Ended
Nov. 30, 2018
Segment Reporting [Abstract]  
Segmented Information

The Company's operations comprise a single reportable segment engaged in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. As the operations comprise a single reportable segment, amounts disclosed in the financial statements for revenue, loss for the period, depreciation and total assets also represent segmented amounts. In addition, all of the Company's long-lived assets are in Canada. The Company’s license and commercialization agreement with Par accounts for substantially all of the revenue of the Company.

 

         November 30,     November 30,     November 30, 
        2018   2017   2016
         $     $     $ 
                 
Revenue          
  United States       1,712,731         5,504,452         2,247,002
              1,712,731         5,504,452         2,247,002
                 
Total assets          
  Canada     11,474,227         7,396,781         7,974,689
                 
Total property and equipment          
  Canada       2,755,993         3,267,551         1,889,638